NASDAQ:VRTX - Nasdaq - US92532F1003 - Common Stock - Currency: USD
VRTX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. Both the profitability and the financial health of VRTX get a neutral evaluation. Nothing too spectacular is happening here. VRTX is not valued too expensively and it also shows a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -4.32% | ||
ROE | -5.99% | ||
ROIC | 17.41% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 37.91% | ||
PM (TTM) | N/A | ||
GM | 86.03% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.01 | ||
Debt/FCF | N/A | ||
Altman-Z | 13.23 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.65 | ||
Quick Ratio | 2.29 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 21.95 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 25.25 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
463.27
-6.28 (-1.34%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 21.95 | ||
P/S | 10.72 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 7.21 | ||
P/tB | 7.95 | ||
EV/EBITDA | 25.25 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -4.32% | ||
ROE | -5.99% | ||
ROCE | 22.04% | ||
ROIC | 17.41% | ||
ROICexc | 25.78% | ||
ROICexgc | 29.25% | ||
OM | 37.91% | ||
PM (TTM) | N/A | ||
GM | 86.03% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.01 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 0.03 | ||
Cap/Depr | 137.41% | ||
Cap/Sales | 2.5% | ||
Interest Coverage | 181.38 | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.65 | ||
Quick Ratio | 2.29 | ||
Altman-Z | 13.23 |